The prognostic value of baseline hematological parameters of peripheral blood in metastatic gastric cancer treated with apatinib

Abstract

Background: There is strong evidence that apatinib is effective in the treatment of third-or later-line advanced metastatic gastric cancer (mGC). Hematology prediction index is a convenient and cheap method to predict the prognosis of disease. However, the prognosis of baseline hematological parameters of peripheral blood, such as neutrophil-to-lymphocyte ratio (NLR), carbohydrate antigen 125 (CA125) and albumin (ALB) on mGC treated with apatinib have not been identified. Methods: We retrospectively analyzed mGC received apatinib between 1 January 2014 and 30 June 2021. Survival analyses were performed using the Kaplan-Meier method and Cox-proportional hazards model. Results: A total of 117 patients were included in this study. The cutoff value of NLR, CA125 and ALB was 2.25, 19.24 U/ml and 37.60 g/L, respectively. The disease control rates (DCR) in the high and low NLR groups were 52.94% and 73.47% (P=0.024); 48.28% and 74.58% (P=0.003) in high and low CA125 groups; 72.97% and 41.86% (P=0.001) in high and low ALB groups. By survival analysis, increasing NLR (P=0.003), CA125 (P<0.001) and decreasing ALB (P<0.001) predicted a shorter PFS after apatinib. NLR (P=0.015), CA125 (P=0.004) and ALB (P=0.005) were significantly predictors for PFS in mGC treated with aptinib. Conclusion: Increasing NLR, CA125 and decreasing ALB were associated with poorer clinical efficiency and prognosis after apatinib treatment.

The expression and clinical significance of serine hydroxymethyltransferase2 in gastric cancer

“…A previous report showed that trastuzumab could be used for patients with Her-2 gene overexpression in combination with chemotherapy ( Meric-Bernstam et al, 2019 ). Apatinib and pembrolizumab have also shown effectiveness in the treatment of advanced GC ( Kawazoe et al, 2020 ; Yang et al, 2022 ). However, their clinical benefits are so limited that the overall effect is not evident.…”

Case report: Apatinib combined with neoadjuvant therapy for primary squamous cell carcinoma of the breast: a case report

“…Apatinib can inhibit the migration and proliferation of endothelial cells promoted by vascular endothelial growth factor and reduce tumor microvessel density, thereby inhibiting tumor angiogenesis (Feng et al, 2021;Zhang et al, 2022a). Apatinib has been used in the third-line treatment of patients with metastatic gastric cancer; that is, the use of apatinib can effectively improve the progression-free survival and total survival of patients with metastatic gastric cancer who have failed to receive more than two chemotherapy regimens (Yang et al, 2022;Zheng et al, 2022). In addition, Chen et al demonstrated that the addition of oral apatinib to conventional chemotherapy regimens prolonged progression-free survival in patients with advanced triple-negative breast cancer (Chen et al, 2021).…”